Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPX-101 + AP1903
- Development stage
- Unknown
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Intradermal, Intravenous
01
Overview
BPX-101 + AP1903 is a **combination immunotherapy** for metastatic castration-resistant prostate cancer (mCRPC), comprising an autologous dendritic cell (DC)-based vaccine (BPX-101) and the small molecule dimerizer rimiducid (AP1903). BPX-101 is manufactured by transducing autologous antigen-presenting cells with an adenoviral vector encoding an inducible CD40 (ih-CD40) protein and loading them with prostate-specific membrane antigen (PSMA) peptides. Upon intradermal administration, BPX-101 is activated in vivo by intravenous rimiducid, which cross-links the modified CD40, leading to localized, temporally controlled DC activation. The overall mechanism is to induce a potent, antigen-specific T-cell response and systemic immune activation against PSMA-expressing prostate tumor cells[1][3][5][7].
- Brand names
- rimiducid
- Other names
- BP GMAX CD1CD1 plus AP1903CD-1 plus AP1903CD 1 plus AP1903
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on BPX-101 + AP1903.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPX-101 + AP1903.